Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

The Collaborative Islet Transplantation Registry Program
The National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in order to establish the The Collaborative Islet Transplantation Registry Program wherein both agencies seek to invite applications that intend to continue initiatives started through the Collaborative Islet Transplantation Registry (CITR).

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---

Funding Opportunity Announcement: Developing Sustainable Healthy Behaviors in Children and Adolescents
The FOA is designed to encourage the use of Exploratory/Developmental Research Grant Awards in employing innovative research studies that would help in determining mechanisms that could promote and influence positive sustainable health behaviors in children and in adolescents, from birth to 18 years old.

---